Trends in Parathyroid Hormone Plasma Concentration in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Study.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 30
- Locations
- 3
- Primary Endpoint
- The change in parathyroid hormone serum concentration during regional citrate anticoagulation continuous renal replacement therapy (CRRT) in the acute phase of critical illness.
Study Overview
Brief Summary
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation continuous renal replacement therapy.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Acute respiratory failure
- •Acute circulatory failure
- •acute kidney injury treated with regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF
- •continuous renal replacement therapy started no later than 48 hours after admission
- •SOFA score 5 or more
Exclusion Criteria
- •age less than 18 years
- •acute liver failure
- •hypercalcemia at admission (total calcium plasma level > 10.6 mg/dL; total ionized calcium plasma level > 1.35 mmol/L
- •parathyroid glands disease
- •end stage renal disease
- •therapeutic plasma exchange
- •extracorporeal membrane oxygenation
- •unfavorable outcome (death) predicted within 72 hours (as assessed by investigator)
- •lack of relatives consent
Outcomes
Primary Outcomes
The change in parathyroid hormone serum concentration during regional citrate anticoagulation continuous renal replacement therapy (CRRT) in the acute phase of critical illness.
Time Frame: 96 hours
The first parathyroid hormone serum level will be measured before the start of CRRT (the zero point) Next measurements will be performed every 12 hours. Minimal number of measurements - 6, maximal - 8 per patient.
Secondary Outcomes
No secondary outcomes reported
Investigators
Tomasz Czarnik, MD PhD
Principal Investigator
Uniwersytecki Szpital Kliniczny w Opolu